What are the factors that influence the distribution of glyconanomedicines?

The distribution of nanodrugs depends on the physicochemical properties of the drug-carrying particles themselves and their surface properties. It also depends on physiological factors such as vascular tissue morphology (e.g., gap size), tissue blood flow rate, and drug properties such as tissue affinity, plasma protein binding rate, and lipid solubility of the drug.

What animal model does CD BioGlyco use for in vivo distribution studies?

We use a variety of animal models for in vivo distribution studies, depending on the purpose of the study and the client's needs. Animal models we commonly use include but are not limited to mouse models, rat models, guinea pig models, rabbit models, and monkey models.

Inquiry

Glyconanoparticle Distribution Study Service

Inquiry

Overview of Glyconanoparticle Distribution Study

In exploring the field of Glyconanoparticle Preclinical Study, CD BioGlyco is committed to providing in-depth Pharmacokinetic Study services, with a particular focus on distribution studies of glyconanoparticles, both in vivo and in vitro. Our services are designed to help you understand the dynamic behavior of glyconanoparticles in biological models and accelerate your project.

Insights into the Secrets of the Distribution of Glyconanoparticles

In Vitro Distribution

Red blood cell distribution and protein binding: Our company offers specialized blood cell distribution and protein-binding assays. We use equilibrium dialysis, ultracentrifugation, and ultrafiltration for plasma protein binding assays. Moreover, we provide binding assay services for other biological matrices, such as binding tissue homogenates, liver microsomes, hepatocytes, and whole blood, and drug distribution studies, such as drug partition ratio in whole blood and plasma.
Uptake assessment: We provide organic anion transporter (OAT), organic cation transporter (OCT), and organic-anion-transporting polypeptides (OATP) uptake assessment services in human embryonic kidney (HEK) and Chinese hamster ovary (CHO) stable transfection system.

In Vivo Distribution

Based on a high-quality GlycoNano™ Platform, we offer many different types of glyconanoparticles for biomedical research. Carrier-based nanomedicines are always undergoing a dynamic process of drug-carrying particle-free drug-carrier material in the body. We offer the following services:

Determination of target organ drug and major metabolite distribution
Distribution of brain regions
Total drug distribution in different tissues
Determination of free and loaded drugs
Study of the distribution of total carrier material in different tissues
Total particle distribution kinetics and drug release kinetics studies in different tissues

Workflow

Schematic of glyconanoparticle distribution study. (CD BioGlyco)

Applications

Glyconanoparticle distribution study provides critical pharmacokinetic data for carrier development and accelerates the drug marketing process.
Glyconanoparticle distribution study can be used for the interaction and mechanistic studies of glyconanoparticles in living organisms.
Glyconanoparticle distribution study can be used for predicting drug interactions, evaluating the toxicity of drugs, predicting pharmacokinetic parameters in humans, and predicting the dosage to be administered.

Advantages of Us

Our team is composed of experienced researchers and provides high-quality experimental data and in-depth distribution studies.
From the synthesis of glyconanoparticles to pharmacokinetic studies, we provide a one-stop service to save clients' time.
We provide not only a distribution study but also the effect of the properties of the glyconanoparticles themselves on the distribution study.

Publication Data

Technology: Electron microscopy, Histological examination, Hematoxylin-eosin staining, Fluorescence spectra, Scanning electron microscope (SEM)

Journal: Nanomaterials

Published: 2021

IF: 4.4

Results: In this study, researchers determined the in vivo distribution of polyethylene glycol-conjugated superparamagnetic iron oxide nanoparticles (SPIONs-PEG). The results showed that after intraperitoneal and intraventricular injections, SPIONs-PEGs enter the circulatory system and are ultimately excreted in the urine. In histological examinations, the skin and spleen showed no abnormal changes and remained within normal limits, while the liver, kidney, brain, and lungs transiently exhibited localized hypoxia or other minor pathological reactions. In addition, the synthesized SPIONs-PEG was able to disperse uniformly in the bloodstream, causing minimal or even negligible damage to the tissues and demonstrating good biocompatibility.

Fig.1 Fluorescence detection profile of the sample. Fig.1 The fluorescence spectra of blood and urine samples. (Suciu, et al., 2021)

Frequently Asked Questions

What are the factors that influence the distribution of glyconanomedicines?
The distribution of nanodrugs depends on the physicochemical properties of the drug-carrying particles themselves and their surface properties. It also depends on physiological factors such as vascular tissue morphology (e.g., gap size), tissue blood flow rate, and drug properties such as tissue affinity, plasma protein binding rate, and lipid solubility of the drug.
What animal model does CD BioGlyco use for in vivo distribution studies?
We use a variety of animal models for in vivo distribution studies, depending on the purpose of the study and the client's needs. Animal models we commonly use include but are not limited to mouse models, rat models, guinea pig models, rabbit models, and monkey models.

CD BioGlyco has a well-trained preclinical research team to help clients provide a satisfactory glyconanoparticle distribution study service. Whatever your challenges in glyconanoparticle distribution research, feel free to contact us for help.

Reference

Suciu, M.; et al. In vivo distribution of poly (ethylene glycol) functionalized iron oxide nanoclusters: an ultrastructural study. Nanomaterials. 2021, 11(9): 2184.